9 September 2016Americas

FTC orders Mylan to divest two generics

The US Federal Trade Commission (FTC) announced yesterday that it has approved a final order in Mylan’s $7.2 billion acquisition of Meda, a Swedish drug maker, deciding that the activity would be anticompetitive.

Mylan has been ordered to divest the US rights to two generic drugs, following the FTC’s order back in July. After a public comment period, the FTC has now confirmed its decision.

The drugs which will be divested are the generics of carisoprodol, a treatment for muscle spasms and stiffness, as well as felbamate, a treatment for refractory epilepsy.

In July the FTC had ordered the divestment because the acquisition would likely have led consumers to pay higher prices, as it would have eliminated competition between Mylan and Meda.

Alvogen Pharma will acquire all of Mylan’s rights and assets related to felbamate tablets, while Indicus Pharma will reacquire the rights to carisoprodol. Mylan had been marketing the drug, but it is owned and manufactured by Indicus.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
31 August 2021   Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.

More on this story

Americas
31 August 2021   Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.

More on this story

Americas
31 August 2021   Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.